Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage
Primary Purpose
Anti-VEGF, Branch Retinal Vein Occlusion, Vitrectomy
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
anti-VEGF
fan-shaped photocoagulation
Sponsored by
About this trial
This is an interventional treatment trial for Anti-VEGF
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years old;
- BRVO is diagnosed
- Vitreous hemorrhage
- Vitreous hemorrhage combined with mild retinal fibrovascular proliferation (early fibrous vascular membrane, thin fibrous vascular membrane, loose retinal adhesion and intact local retinal structure)
Exclusion Criteria:
- BRVO combined with severe retinal fibrovascular proliferation (long-term fibrovascular membrane, thick fibrous vascular membrane and tightly attached to the retina, deformation of local retinal, retinal tear or suspension of retinal vein )
- BRVO combined with retinal detachment
- Retinal veins are completely whitened
- iris neovascularization or neovascular glaucoma
- Combined glaucoma
- combined with other retinopathy
- Received anti-VEGF treatment within 3 months before surgery
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
anti-VEGF
fan-shaped photocoagulation
Arm Description
vitreoretinal surgery combined with intraoperative anti-VEGF
vitreoretinal surgery combined with fan-shaped photocoagulation
Outcomes
Primary Outcome Measures
Mean change from baseline in best-corrected visual acuity (BCVA)
Assessed using the ETDRS protocol
Secondary Outcome Measures
Mean change from baseline in visual field
Assessed on Humphery(30-2 and 60-4)
chang from baseline in structure of retina
Assessed on Optical Coherence Tomography(OCT)
chang from baseline in retinal neovascularization
Assessed on Fundus Fluorescein Angiography(FFA)
Full Information
NCT ID
NCT03637283
First Posted
August 15, 2018
Last Updated
August 16, 2018
Sponsor
Wenzhou Medical University
1. Study Identification
Unique Protocol Identification Number
NCT03637283
Brief Title
Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage
Official Title
Feasibility Study of Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2018 (Anticipated)
Primary Completion Date
December 1, 2020 (Anticipated)
Study Completion Date
December 1, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Wenzhou Medical University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To evaluate the efficacy and safety of Anti-VEGF instead of intraoperative fan-shaped photocoagulation in BRVO combined with vitreous hemorrhage.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anti-VEGF, Branch Retinal Vein Occlusion, Vitrectomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
anti-VEGF
Arm Type
Experimental
Arm Description
vitreoretinal surgery combined with intraoperative anti-VEGF
Arm Title
fan-shaped photocoagulation
Arm Type
Active Comparator
Arm Description
vitreoretinal surgery combined with fan-shaped photocoagulation
Intervention Type
Procedure
Intervention Name(s)
anti-VEGF
Intervention Description
vitreoretinal surgery combined with intraoperative anti-VEGF
Intervention Type
Procedure
Intervention Name(s)
fan-shaped photocoagulation
Intervention Description
vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
Primary Outcome Measure Information:
Title
Mean change from baseline in best-corrected visual acuity (BCVA)
Description
Assessed using the ETDRS protocol
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Mean change from baseline in visual field
Description
Assessed on Humphery(30-2 and 60-4)
Time Frame
3 years
Title
chang from baseline in structure of retina
Description
Assessed on Optical Coherence Tomography(OCT)
Time Frame
3 years
Title
chang from baseline in retinal neovascularization
Description
Assessed on Fundus Fluorescein Angiography(FFA)
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years old;
BRVO is diagnosed
Vitreous hemorrhage
Vitreous hemorrhage combined with mild retinal fibrovascular proliferation (early fibrous vascular membrane, thin fibrous vascular membrane, loose retinal adhesion and intact local retinal structure)
Exclusion Criteria:
BRVO combined with severe retinal fibrovascular proliferation (long-term fibrovascular membrane, thick fibrous vascular membrane and tightly attached to the retina, deformation of local retinal, retinal tear or suspension of retinal vein )
BRVO combined with retinal detachment
Retinal veins are completely whitened
iris neovascularization or neovascular glaucoma
Combined glaucoma
combined with other retinopathy
Received anti-VEGF treatment within 3 months before surgery
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yong Wei, M.D
Phone
+86 15057551266
Email
weiyongdoctor@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Wei Lin, M.D
Phone
+86 13587560390
Email
linweiysg@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yong Wei, M.D
Organizational Affiliation
The Eye Hospital of Wenzhou Medical University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage
We'll reach out to this number within 24 hrs